PREZISTA/PREZCOBIX/REZOLSTA/SYMTUZA — Sales to customers (Note 9)
Johnson & Johnson PREZISTA/PREZCOBIX/REZOLSTA/SYMTUZA — Sales to customers (Note 9) increased by 15.7% to $443.00M in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 9.9%, from $403.00M to $443.00M. Over 4 years (FY 2021 to FY 2025), PREZISTA/PREZCOBIX/REZOLSTA/SYMTUZA — Sales to customers (Note 9) shows a downward trend with a -6.7% CAGR. This is a positive signal — higher values indicate stronger performance for this metric.
Analysis
How to read this metric
An increase indicates strong market adoption and sustained demand for the product line, while a decrease may signal increased generic competition or a shift in treatment standards.
Detailed definition
This metric represents the total net revenue generated from the sale of a specific portfolio of HIV antiviral medication...
Peer comparison
Comparable to revenue reporting for specific therapeutic drug franchises or product lines in other major pharmaceutical companies.
jnj_segment_prezista_prezcobix_rezolsta_symtuza_sales_to_customers_note_9Historical Data
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $505.00M | $517.00M | $515.00M | $501.00M | $464.00M | $485.00M | $493.00M | $477.00M | $491.00M | $447.00M | $439.00M | $418.00M | $438.00M | $449.00M | $407.00M | $403.00M | $396.00M | $397.00M | $383.00M | $443.00M |
| QoQ Change | — | +2.4% | -0.4% | -2.7% | -7.4% | +4.5% | +1.6% | -3.2% | +2.9% | -9.0% | -1.8% | -4.8% | +4.8% | +2.5% | -9.4% | -1.0% | -1.7% | +0.3% | -3.5% | +15.7% |
| YoY Change | — | — | — | — | -8.1% | -6.2% | -4.3% | -4.8% | +5.8% | -7.8% | -11.0% | -12.4% | -10.8% | +0.4% | -7.3% | -3.6% | -9.6% | -11.6% | -5.9% | +9.9% |
Similar Metrics at Other Companies
Frequently Asked Questions
- What is Johnson & Johnson's prezista/prezcobix/rezolsta/symtuza — sales to customers (note 9)?
- Johnson & Johnson (JNJ) reported prezista/prezcobix/rezolsta/symtuza — sales to customers (note 9) of $443.00M in Q1 2026.
- How has Johnson & Johnson's prezista/prezcobix/rezolsta/symtuza — sales to customers (note 9) changed year-over-year?
- Johnson & Johnson's prezista/prezcobix/rezolsta/symtuza — sales to customers (note 9) increased by 9.9% year-over-year, from $403.00M to $443.00M.
- What is the long-term trend for Johnson & Johnson's prezista/prezcobix/rezolsta/symtuza — sales to customers (note 9)?
- Over 4 years (2021 to 2025), Johnson & Johnson's prezista/prezcobix/rezolsta/symtuza — sales to customers (note 9) has grown at a -6.7% compound annual growth rate (CAGR), from $2.08B to $1.58B.
- What does prezista/prezcobix/rezolsta/symtuza — sales to customers (note 9) mean?
- The total revenue generated from the sale of a specific group of HIV treatment medications.